Overview

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

Status:
Recruiting

Trial end date:
2025-03-05

Target enrollment:

Participant gender:

Summary

A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborators:

The European Network for Gynaecological Oncological Trial groups (ENGOT)
The Gynecologic Oncology Group (GOG) Foundation Inc

Treatments:

Albumin-Bound Paclitaxel
Antibodies, Monoclonal
Carboplatin
Durvalumab
Olaparib
Paclitaxel